Discover a study that explores how PARP inhibition with niraparib may offer new therapeutic potential for advanced melanoma ...

INmune Bio's ATM offering raises $19M ahead of Phase II results, but disappointing data and dilution signal risks. Read here ...

IMM2510, a differentiated PD-L1xVEGF bispecific antibody with upcoming data in H2 2025. Click to read why TIL is a Hold.

The drug, which Repare recently sidelined, has shown promising activity in a patient with ALT-positive melanoma that researchers want to study in others.

VIDEO: Addressing inadequate response to JAK inhibitorsEditor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of ...

Marstacimab is a tissue factor pathway inhibitor antagonist approved under the brand name Hympavzi.

The privately funded basket trial makes good on its aim to enroll underrepresented groups amid a DEI-hostile federal funding ...